FDA Approves Cosibelimab-ipdl for Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma By Ogkologos - January 31, 2025 230 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Study CK-301-101 Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR Black Patients Are More Likely to Die of Cancer—Here’s How One... December 21, 2021 Study Tests Immunotherapy in People with Cancer and Autoimmune Diseases August 26, 2019 Targeted Therapy Based on Molecular Profiling of Malignant Mesothelioma Tumours Is... October 19, 2020 EMA Recommends to Extend the Indications for Tislelizumab May 8, 2025 Load more HOT NEWS 4 Tips from Oncology Dietitians for Healthier Eating During Cancer Discovering the BRCA2 gene – 25 years on Rusfertide Nearly Eliminates Need for Phlebotomies to Treat Polycythemia Vera 2023 ASCO Annual Meeting Research Round Up: New Research in Treating...
